Trial Profile

An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ifidancitinib (Primary)
Indications Alopecia
Focus Therapeutic Use
Sponsors Aclaris Therapeutics

Most Recent Events

16 Nov 2020 Status changed from active, no longer recruiting to completed.
08 Aug 2019 According to an Aclaris Therapeutics media release, If the 12-month data from this trial are positive, the company intends to seek a strategic partner to further develop ATI-502 for this indication.
17 Jun 2019 According to an Aclaris Therapeutics media release, the 12-month results from this trial are expected by year end 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com